Orion Infusion Ltd
Orion Infusion Ltd maintains a debt-to-equity ratio of 0.98, indicating a balanced capital structure with moderate leverage. The company's liquidity position is assessed as medium, with a current ratio of 0.94, suggesting limited short-term liquidity cushion. Free cash flow of $24.7 million supports operational flexibility, though the absence of cash and equivalents highlights a reliance on cash flow generation rather than liquidity reserves. Profitability metrics show a return on equity of 10.74% and a return on assets of 4.13%, both below the median for the Pharmaceuticals industry. The company's operating margin of 12.97% (calculated from operating income of $86.3 million on revenue of $665 million) is also below the industry median, indicating room for improvement in cost control or pricing power. Geographically, Orion Infusion's revenue is concentrated in a single market, with no disclosed diversification across regions or product lines. This concentration increases exposure to local regulatory, economic, and competitive shifts. Segment-wise, the company operates as a single business unit, with no material diversification across therapeutic areas or product categories. Outl
Business. Orion Infusion Ltd (ORIN.DH) is a pharmaceutical company engaged in the development and sale of medical products. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Headquarters location and specific operating segments are not disclosed in the available data. The company is primarily listed under the ticker ORIN.DH.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Orion Infusion Ltd (ORIN.DH) is a pharmaceutical company engaged in the development and sale of medical products. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. Headquarters location and specific operating segments are not disclosed in the available data. The company is primarily listed under the ticker ORIN.DH.
Orion Infusion Ltd maintains a debt-to-equity ratio of 0.98, indicating a balanced capital structure with moderate leverage. The company's liquidity position is assessed as medium, with a current ratio of 0.94, suggesting limited short-term liquidity cushion. Free cash flow of $24.7 million supports operational flexibility, though the absence of cash and equivalents highlights a reliance on cash flow generation rather than liquidity reserves.
Profitability metrics show a return on equity of 10.74% and a return on assets of 4.13%, both below the median for the Pharmaceuticals industry. The company's operating margin of 12.97% (calculated from operating income of $86.3 million on revenue of $665 million) is also below the industry median, indicating room for improvement in cost control or pricing power.
Geographically, Orion Infusion's revenue is concentrated in a single market, with no disclosed diversification across regions or product lines. This concentration increases exposure to local regulatory, economic, and competitive shifts. Segment-wise, the company operates as a single business unit, with no material diversification across therapeutic areas or product categories.
Outlook for the current fiscal year shows a projected revenue increase of 12.5% year-over-year, driven by new product launches and expanded distribution. For the next fiscal year, revenue is expected to grow by 8.2%, reflecting continued market penetration and stable demand for IV therapies. Historical revenue growth has averaged 9.3% annually over the past three years.
Risk factors include a medium liquidity risk due to the absence of cash and equivalents and a current ratio below 1. The company has a low dilution risk, with no near-term pressure from share issuance or convertible debt. However, the risk assessment flags a negative net cash position after subtracting total debt, which could constrain flexibility in capital allocation.
Recent events include the filing of a 10-K annual report disclosing the company's financial position and risk factors, as well as a Q4 earnings call transcript highlighting progress in product development and market expansion.
- Orion Infusion Ltd operates with a balanced capital structure but limited liquidity reserves.
- Profitability metrics are below industry medians, suggesting potential for operational improvement.
- Revenue is concentrated in a single market, increasing exposure to regional risks.
- The company is projected to grow revenue by 12.5% in the current fiscal year and 8.2% in the next.
- Liquidity risk is moderate, with no immediate dilution pressure.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Orion Infusion Ltd Market data — financials · 2026-05-28